Table 2.

Clinical characteristics of patients investigated longitudinally

Patient A
Patient B
Patient C
Patient D
Age, y   33   57   26   62  
Sex   Woman   Man   Man   Man  
CDC stage   C3   A2   B3   C3  
Treatment regimen   D4T, 3TC, r-LPV   D4T, 3TC, EFV   AZT, 3TC, EFV   AZT, 3TC, NVP  
CD4 count at 1st endoscopy, cells per μL   43   560   158   184  
CD4 count at 2nd endoscopy, cells per μL   110   875   282   512  
HIV load at 1st endoscopy, log10 copies per mL   5.88   2.38*  6.05   5.09  
Months with HIV load below 50 copies per mL before second endoscopy
 		 3
 		 6
 		 4
 		 25
 
Patient A
Patient B
Patient C
Patient D
Age, y   33   57   26   62  
Sex   Woman   Man   Man   Man  
CDC stage   C3   A2   B3   C3  
Treatment regimen   D4T, 3TC, r-LPV   D4T, 3TC, EFV   AZT, 3TC, EFV   AZT, 3TC, NVP  
CD4 count at 1st endoscopy, cells per μL   43   560   158   184  
CD4 count at 2nd endoscopy, cells per μL   110   875   282   512  
HIV load at 1st endoscopy, log10 copies per mL   5.88   2.38*  6.05   5.09  
Months with HIV load below 50 copies per mL before second endoscopy
 		 3
 		 6
 		 4
 		 25
 

D4T indicates stavudine; 3TC, lamivudine; r-LPV, ritonavir-boosted lopinavir; EFV, efavirenz; AZT, zidovudine; NVP, nevirapine.

*

Patient B had already been treated by HAART for 8 weeks at the time of the first endoscopy.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal